Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
RCEL
RCEL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RCEL News
AVITA Medical to Host Investor Webinar on Q4 and Full-Year 2025 Results
2d ago
Newsfilter
AVITA Medical Q4 2025 Earnings Call Insights
3d ago
seekingalpha
AVITA Medical to Announce Q4 Earnings on February 12
4d ago
seekingalpha
Bragar Eagel & Squire Investigates Soleno, Avita, and Coty for Potential Securities Violations
Jan 08 2026
Globenewswire
AVITA Medical Appoints Joe Woody as Board Director, Lou Panaccio Retires
Jan 05 2026
Globenewswire
AVITA Medical CEO to Present at 44th Annual J.P. Morgan Healthcare Conference
Dec 18 2025
Globenewswire
Agilon Health CEO Resignation Triggers 27% Stock Drop
Dec 03 2025
Globenewswire
Nasdaq Analyst Becomes Optimistic; Check Out the Top 5 Upgrades for Thursday
Nov 20 2025
Benzinga
Bragar Eagel & Squire, P.C. Urges Agilon, Soleno, Avita, and Coty Investors to Reach Out About Current Investigations
Nov 18 2025
Globenewswire
Bragar Eagel & Squire, P.C. Launches Investigation into Agilon, Soleno, Avita, and Coty, Urging Investors to Reach Out to the Firm
Nov 10 2025
Globenewswire
AVITA Medical (RCEL) Third Quarter 2025 Earnings Call Transcript
Nov 07 2025
NASDAQ.COM
Avita projects revenue rebound with $70M–$74M forecast for 2025 after gaining reimbursement clarity.
Nov 06 2025
SeekingAlpha
Fresh Strong Sell Stocks for October 31st
Oct 31 2025
NASDAQ.COM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AVITA Medical, Inc. - RCEL
Oct 23 2025
PRnewswire
AVITA Medical (RCEL): Assessing Valuation Following CEO Transition, Board Changes, and Revised Financial Outlook
Oct 20 2025
Yahoo Finance
D. Boral Capital Reiterates Buy Rating on AVITA Medical with $14 Price Target Intact
Oct 17 2025
Benzinga
Show More News
